Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare hereditary Transthyretin (TTR)-related systemic amyloidosis (ATTR) with predominant cardiac involvement resulting from myocardial infiltration of abnormal amyloid protein.
Biomarker and diagnostic research for ATTRV122I amyloidosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
115 publications have been identified in PubMed for ATTRV122I amyloidosis. Research spans Review / Meta-Analysis (71%), Other (8%), and Case Report / Case Series (8%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 82 | 71% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 3:31 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ATTRV122I amyloidosis
Other research |
9 |
8% |
Patient case studies | 9 | 8% |
Disease patterns and progression | 9 | 8% |
Laboratory research | 4 | 3% |
Testing and diagnosis research | 1 | 1% |
Clinical study results | 1 | 1% |
Ahmed F (2026). [PMID: 41618157](https://pubmed.ncbi.nlm.nih.gov/41618157/). *BMC Cardiovasc Disord*. [Epidemiology / Natural History]
Cervantes CE (2026). [PMID: 38865984](https://pubmed.ncbi.nlm.nih.gov/38865984/). *Am J Nephrol*. [Review / Meta-Analysis]
Gomes CM (2026). [PMID: 41886557](https://pubmed.ncbi.nlm.nih.gov/41886557/). *Science*. [Review / Meta-Analysis]
Ferrari Chen YF (2025). [PMID: 40232627](https://pubmed.ncbi.nlm.nih.gov/40232627/). *Curr Heart Fail Rep*. [Review / Meta-Analysis]
Zvida-Bloch T (2025). [PMID: 40211787](https://pubmed.ncbi.nlm.nih.gov/40211787/). *Br J Haematol*. [Review / Meta-Analysis]
Vasstrand HJ (2025). [PMID: 40457206](https://pubmed.ncbi.nlm.nih.gov/40457206/). *BMC Nephrol*. [Epidemiology / Natural History]
Triposkiadis F (2025). [PMID: 39954876](https://pubmed.ncbi.nlm.nih.gov/39954876/). *Curr Probl Cardiol*. [Review / Meta-Analysis]
Fontana M (2025). [PMID: 39797879](https://pubmed.ncbi.nlm.nih.gov/39797879/). *JACC Cardiovasc Imaging*. [Review / Meta-Analysis]
Kashchavtseva NA (2025). [PMID: 40327620](https://pubmed.ncbi.nlm.nih.gov/40327620/). *Ter Arkh*. [Case Report / Case Series]
Tang J (2025). [PMID: 41002209](https://pubmed.ncbi.nlm.nih.gov/41002209/). *R I Med J (2013)*. [Review / Meta-Analysis]
AI-curated news mentioning ATTRV122I amyloidosis
Updated Aug 12, 2026
BridgeBio Pharma's ATTR treatment, Attruby, is experiencing a robust launch, indicating strong market demand. In contrast, Alnylam has reduced its full-year sales forecast for Amvuttra, signaling potential challenges in the competitive landscape.
Following the Phase 3 failure of AstraZeneca and Ionis Pharmaceuticals' therapy for transthyretin amyloid cardiomyopathy, five companies are reassessing their strategies in this space. The article provides insights into the current status of these contenders and their assets.